# "Extended" (Alternate Day) Antipsychotic Dosing

> **NCT04478838** · PHASE4 · RECRUITING · sponsor: **Centre for Addiction and Mental Health** · enrollment: 120 (estimated)

## Conditions studied

- Schizophrenia and Related Disorders
- Drug Administration Schedule
- Drug Therapy
- Antipsychotic Agents

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine
- **DRUG:** paliperidone

## Key facts

- **NCT ID:** NCT04478838
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-06
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478838, ""Extended" (Alternate Day) Antipsychotic Dosing". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04478838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*